Literature Highlights - July 2022
This highlight deck is comprised of 6 papers
Each month the Lupus Forum Steering Committee selects the latest published original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
Literature Highlights - June 2022
This highlight deck is comprised of 4 papers
Keywords:
Anifrolumab, Belimumab, Treatment Comparison, Baricitinib, Anti-dsDNA, Filgotinib, Lanraplenib
Literature Highlights - May 2022
This highlight deck is comprised of 7 papers
Keywords:
Prolonged remission, DORIS, End-organ manifestation, Multiethnic, Belimumab, Organ damage, Iberdomide, Anifrolumab, SLICC frailty index, Voclosporin
Literature Highlights - April 2022
This highlight deck is comprised of 5 papers
Keywords:
Obinutuzumab, Rituximab, Anifrolumab, Lupus nephritis, Severe SLE, LLDAS, QoL, Fatigue
Literature Highlights - March 2022
This highlight deck is comprised of 5 papers
Keywords:
Anifrolumab, Lupus nephritis, TULIP trials, PROs, Tacrolimus, Mycophenolate, Corticosteroids, Iberdomide, SLICC frailty index
Literature Highlights - February 2022
This highlight deck is comprised of 6 papers
Keywords:
Belimumab, Lupus nephritis, BLISS, Anifrolumab, Severe SLE, TULIP trials, Organ domains, BILAG, EULAR, CV risk, Antimalarials, B-cell subset, IgG
Literature Highlights - January 2022
This highlight deck is comprised of 11 papers
Keywords:
Flare, Hydroxychloroquine, SLICC frailty index, Real-world, QoL, SLE damage, IFNGS, Biomarkers, Glucocorticoids, Cutaneous disease, Belimumab, Fertility, Acute myocardial infarction, LLDAS, Severe SLE
Literature Highlights December 2021
This highlight deck is comprised of 10 papers
Keywords:
Ustekinumab, EULAR, ACR, Long-term damage, Cutaneous lupus erythematosus, Baricitinib, B-cell depletion, Rituximab, Obinutuzumab, Lupus nephritis, Belimumab, Fatigue, Antimalarials, Prednisolone
Literature Highlights November 2021
This highlight deck is comprised of 8 papers
Keywords:
Belimumab, Rituximab, ACR, Antimalarials, Hydroxychloroquine, CV disease, SLE subgroups, Autoantibody status, Productivity with SLE, EULAR, Damage accrual, Economic burden, PROs
Literature Highlights October 2021
This highlight deck is comprised of 9 papers